Multiplex Assay Kit for Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay)

VGR; VGR1; Vegetal Related Growth Factor(TGFB-Related); VG-1-related protein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 82-92 86
EDTA plasma(n=5) 88-96 92
heparin plasma(n=5) 96-104 101
sodium citrate plasma(n=5) 83-96 87

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 78-99% 98-105% 79-93% 91-98%
EDTA plasma(n=5) 90-99% 88-95% 78-104% 83-104%
heparin plasma(n=5) 92-101% 78-96% 88-105% 92-105%
sodium citrate plasma(n=5) 78-102% 97-105% 81-89% 92-104%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:BMP6) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
International Journal of Cardiology Valvular osteoclasts in calcification and aortic valve stenosis severity PubMed: 23452891
Polskie Archiwum Medycyny Wewn Trznej New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis PubMed: 23111696
PLoS ONE A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches Plosone: Source
journal of biomedical materials research part b-applied biomaterials In vitro chondrogenesis by BMP6 gene therapy Pubmed: 23077084
Journal of Clinical Pathology Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C PubMed: 26290259
Clinical and Experimental Pharmacology and Physiology Bone morphogenetic protein 6—a possible new player in pathophysiology of heart failure pubmed:27592865
International Journal of Biological Macromolecules SEQUENTIAL IGF-1 AND BMP-6 RELEASING CHITOSAN/ALGINATE/PLGA HYBRID SCAFFOLDS FOR PERIODONTAL REGENERATION pubmed:28601648
Elife The transcriptomic and epigenetic map of vascular quiescence in the continuous lung endothelium Pubmed:29749927
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPA646Ra01 Recombinant Bone Morphogenetic Protein 6 (BMP6) Positive Control; Immunogen; SDS-PAGE; WB.
PAA646Ra01 Polyclonal Antibody to Bone Morphogenetic Protein 6 (BMP6) WB; IHC; ICC; IP.
LAA646Ra71 Biotin-Linked Polyclonal Antibody to Bone Morphogenetic Protein 6 (BMP6) WB; IHC; ICC.
MAA646Ra21 Monoclonal Antibody to Bone Morphogenetic Protein 6 (BMP6) WB; IHC; ICC; IP.
SEA646Ra ELISA Kit for Bone Morphogenetic Protein 6 (BMP6) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA646Ra Multiplex Assay Kit for Bone Morphogenetic Protein 6 (BMP6) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.